| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.90▼ | 2.00▼ | 2.00▼ | 1.96▼ | 3.44▼ |
| MA10 | 2.00▼ | 2.09▼ | 2.12▼ | 2.18▼ | 4.93▼ |
| MA20 | 2.26▼ | 2.71▼ | 2.93▼ | 3.41▼ | N/A |
| MA50 | 3.74▼ | 4.30▼ | 4.49▼ | 5.27▼ | N/A |
| MA100 | 5.07▼ | 5.93▼ | 6.36▼ | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.060▲ | 0.017▲ | -0.003▼ | -0.061▼ | N/A |
| RSI | 18.929▼ | 18.789▼ | 18.721▼ | 19.245▼ | N/A |
| STOCH | 2.439▼ | 4.848▼ | 3.634▼ | 4.014▼ | N/A |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -99.365▼ | N/A |
| CCI | -103.299▼ | -96.151 | -86.536 | -72.194 | N/A |
|
Monday, October 26, 2026 06:18 AM
Niki BioSolutions, Inc. (NASDAQ: NIKI) announced that its subsidiary, DiamiR Biosciences Corp., received Clinical Laboratory Evaluation Program (CLEP) approval from the New York State Department of ...
|
|
Monday, October 26, 2026 02:15 AM
NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research useNEW HAVEN, CT ...
|
|
Friday, October 23, 2026 05:00 AM
Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer’s clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/10/26 | 1.94 | 1.94 | 1.81 | 1.83 | 5,100 |
| 22/10/26 | 1.92 | 1.95 | 1.81 | 1.86 | 14,501 |
| 21/10/26 | 1.91 | 2.10 | 1.83 | 2.00 | 10,499 |
| 20/10/26 | 2.07 | 2.14 | 1.90 | 2.03 | 22,316 |
| 19/10/26 | 2.11 | 2.24 | 1.91 | 2.08 | 9,563 |
| 16/10/26 | 2.32 | 2.40 | 1.94 | 2.03 | 24,914 |
| 15/10/26 | 2.32 | 2.66 | 2.12 | 2.22 | 51,862 |
| 14/10/26 | 2.58 | 2.6499 | 2.1451 | 2.1451 | 21,359 |
| 13/10/26 | 2.99 | 3.22 | 2.625 | 2.625 | 24,755 |
| 12/10/26 | 3.84 | 3.84 | 3.02 | 3.02 | 15,059 |
|
|
||||
|
|
||||
|
|